Literature DB >> 18251493

Azetidine based transition state analogue inhibitors of N-ribosyl hydrolases and phosphorylases.

Gary B Evans1, Richard H Furneaux, Ben Greatrex, Andrew S Murkin, Vern L Schramm, Peter C Tyler.   

Abstract

N-ribosyl phosphorylases and hydrolases catalyze nucleophilic displacement reactions by migration of the cationic ribooxacarbenium carbon from the fixed purine to phosphate and water nucleophiles, respectively. As the lysis reaction progresses along the reaction coordinate, the distance between the purine and carbocation increases and the distance between carbocation and nucleophile decreases. Immucillin-H and DADMe-immucillin-H have been shown previously to be potent inhibitors of purine nucleoside phosphorylases and lie more toward the reactant and products side of this reaction coordinate, respectively. Both these enzyme inhibitors, which are currently in human clinical trials for different indications, are chiral and expensive to manufacture. We now report the synthesis of azetidine analogues of the DADMe-immucillins, which, despite their lack of stereochemical complexity, remain potent inhibitors (equilibrium dissociation constants as low as 229 pM) of purine nucleoside phosphorylase (PNP), methylthioadenosine phosphorylase (MTAP), and methylthioadenosine nucleosidase (MTAN), with potential utility as drug candidates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18251493     DOI: 10.1021/jm701265n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Synthesis and evaluation of novel azetidine analogs as potent inhibitors of vesicular [3H]dopamine uptake.

Authors:  Derong Ding; Justin R Nickell; Agripina G Deaciuc; Narsimha Reddy Penthala; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2013-08-11       Impact factor: 3.641

2.  A beta-fluoroamine inhibitor of purine nucleoside phosphorylase.

Authors:  Jennifer M Mason; Andrew S Murkin; Lei Li; Vern L Schramm; Graeme J Gainsford; Brian W Skelton
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

Review 3.  Enzymatic transition states, transition-state analogs, dynamics, thermodynamics, and lifetimes.

Authors:  Vern L Schramm
Journal:  Annu Rev Biochem       Date:  2011       Impact factor: 23.643

4.  Enzyme-ligand interactions that drive active site rearrangements in the Helicobacter pylori 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase.

Authors:  Donald R Ronning; Natalie M Iacopelli; Vidhi Mishra
Journal:  Protein Sci       Date:  2010-12       Impact factor: 6.725

5.  Third-generation immucillins: syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase.

Authors:  Keith Clinch; Gary B Evans; Richard F G Fröhlich; Richard H Furneaux; Peter M Kelly; Laurent Legentil; Andrew S Murkin; Lei Li; Vern L Schramm; Peter C Tyler; Anthony D Woolhouse
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

6.  Molecular dynamics study of the effect of active site protonation on Helicobacter pylori 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase.

Authors:  Mustafa Tekpinar; Ahmet Yildirim; Tsjerk A Wassenaar
Journal:  Eur Biophys J       Date:  2015-08-08       Impact factor: 1.733

7.  Characterization of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidases from Borrelia burgdorferi: Antibiotic targets for Lyme disease.

Authors:  Kenneth A Cornell; Reece J Knippel; Gerald R Cortright; Meghan Fonken; Christian Guerrero; Amy R Hall; Kristen A Mitchell; John H Thurston; Patrick Erstad; Aoxiang Tao; Dong Xu; Nikhat Parveen
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-10-31       Impact factor: 3.770

Review 8.  Mannich bases in medicinal chemistry and drug design.

Authors:  Gheorghe Roman
Journal:  Eur J Med Chem       Date:  2014-10-30       Impact factor: 6.514

9.  Novel Azetidine-Containing TZT-1027 Analogues as Antitumor Agents.

Authors:  Qi Yan; Yujie Wang; Wei Zhang; Yingxia Li
Journal:  Mar Drugs       Date:  2016-04-28       Impact factor: 5.118

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.